UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000036762
Receipt No. R000041878
Scientific Title Examination of the influence that continued intake of rosemary extract exerts stress and cognitive function from stress
Date of disclosure of the study information 2019/05/27
Last modified on 2019/05/28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Examination of the influence that continued intake of rosemary extract exerts stress and cognitive function from stress
Acronym Examination of the influence that continued intake of rosemary extract exerts stress and cognitive function from stress
Scientific Title Examination of the influence that continued intake of rosemary extract exerts stress and cognitive function from stress
Scientific Title:Acronym Examination of the influence that continued intake of rosemary extract exerts stress and cognitive function from stress
Region
Japan

Condition
Condition Healthy subjects
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate the effects of continuous intake of rosemary extract for 4 weeks on stress and cognitive function caused by stress in healthy Japanese men aged 20 to 65 years old.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes POMS II (all items version),Cognitrax
Key secondary outcomes VAS questionnaire(6 items),Blood catecholamine 3 fraction,d-ROM,BDNF,Salivary cortisol

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 4-week intake of the test food
Interventions/Control_2 4-week intake of the placebo food
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
65 years-old >
Gender Male
Key inclusion criteria 1)Japanese male and aged between 20 and 65 years old at the time of the informed.
2)Subject who feels fatigue and routinely.
3)Subject who is Beck Depression Inventory(BDI)less than 21 points.
4)Subject who has understood the purpose of the study, and agreed to participate it by signing the written informed consent.
Key exclusion criteria 1)Subject who is taking medication or under medical treatment.
2)Subject who is under exercise therapy or dietetic therapy.
3)Subject who has an allergy for test food.
4)Subject who has or had a history of either medicine or alcohol dependence syndrome.
5)Subject who has or had a history of mental illness (depression) or sleep disturbance.
6)Subject who is on a night-shift or is a shift worker.
7)Subject who currently have a smoking habit.
8)Subject whose lifestyle is extremely irregular.
9)Subject who has an unbalanced diet.
10)Subject who regularly drink energy drinks.
11)Subject who has current disease or history of diabetes, liver disease (hepatitis), kidney disease, serious disease such as heart disease, thyroid disease, adrenal disease, other metabolic diseases.
12)Subject who use stress, health foods, supplements, and medicines that affect cognitive function.
13)Subject who regularly take commercially available sleep improving drugs and sleep inducing agents.
14)Subject who has participated in other clinical studies within the past 3 months from the day of the consent acquisition or who is planning to participate in other clinical studies during the current study.
15)Subject who has blood drawn 200mL within the past 1 months or 400mL within the past 3 months from the day of the consent acquisition.
16)Subject who can't keep the daily records.
17)Subject who is judged as an inappropriate candidate according to the screening data.
18)Subject who is considered as an inappropriate candidate by the doctor in charge.
Target sample size 42

Research contact person
Name of lead principal investigator
1st name Kazuhiro
Middle name
Last name Ogura
Organization S&B FOODS INC.
Division name Development and manufacturing group-Central Research Institute-Technology Research and Development Unit
Zip code 174-8651
Address 38-8, Miyamoto-cho Itabashi-ku, Tokyo
TEL 03-3558-5531
Email kazuhiro_ogura@sbfoods.co.jp

Public contact
Name of contact person
1st name Daisuke
Middle name
Last name Ochitani
Organization HUMA R&D CORP
Division name Clinical Development Division
Zip code 108-0014
Address Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
TEL 03-3431-1260
Homepage URL
Email ochitani@huma-rd.co.jp

Sponsor
Institute HUMA R&D CORP
Institute
Department

Funding Source
Organization S&B FOODS INC.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Ethics Committees of Nihonbashi Egawa Clinic
Address 2F Kotobuki Build. 1-27-12 Yaesu Chuo-ku, Tokyo 103-0028 Japan
Tel 03-5204-0311
Email jim@medipharma.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2019 Year 05 Month 27 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2019 Year 04 Month 03 Day
Date of IRB
2019 Year 04 Month 15 Day
Anticipated trial start date
2019 Year 05 Month 27 Day
Last follow-up date
2019 Year 07 Month 05 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2019 Year 05 Month 16 Day
Last modified on
2019 Year 05 Month 28 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041878

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.